In a deal that will transform the pharmaceutical industry, Pfizer announced that it will buy rival Hospira for $16 billion, reports Wall Street Journal.

The purchase is expected to make Pfizer a leading player in the emerging market for lower-priced versions of costly biotech drugs, according to the article.

Read more below: